News
Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...
From a horrific motorcycle accident to his first Kentucky Derby, jockey Joseph Ramos is determined to "let the comeback be ...
The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in patients aged 12 and older who remain symptomatic despite antihistamine treatment ...
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...
Zacks Investment Research on MSN8h
Sanofi & Regeneron's Dupixent Receives FDA Nod for UrticariaSanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...
Chambersburg Public Opinion on MSN13h
What to know about measles as deadly disease makes comebackBy late February, a 6-year-old unvaccinated girl died of measles-related pneumonia — the first U.S. measles death since 2015 ...
Skin and subcutaneous diseases account for 44.84 million DALYs globally in 2021, ranking seventh in disability burden.
In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback